NEW PROBIOTIC PRODUCT FOR PREVENTION AND TREATMENT OF ENTERITIS AND RESPIRATORY DISEASES OF FARM STOCK - Biochemistry and Biotechnology: Research and Development - page 106

species. A complex of therapeutic-prophylactic measures aimed at correction of
microecological intestinal abnormalities includes: 1) treatment of principal pathology, 2)
creating conditions promoting normalization of intestinal microbiocenosis, 3) application of
agents with target positive effect on gut microflora.
It was convincingly proved that regular administration of antibiotic leads to pathogen
resistance so that formerly efficient medicines lose efficiency [3]. In particular, antibiotic
treatment of gastrointestinal diseases results in shift of quantitative and qualitative
composition of facultatively pathogenic and normal intestinal microbiota defined as
bacteriosis - one of the key factors determining progress of pathologies with diarrhea
syndrome.
The afore-mentioned circumstances necessitated development of a novel generation of
safe and effective biopreparations aimed at correction of intestinal biocenosis and fostering of
animal immunity. In recent years probiotics based on living microbial species and their
structural components and metabolites beneficial to gut microbiota find wide use as
substitution agents accelerating recovery of natural gastrointestinal microflora in young farm
stock after antimicrobial drug therapy. [4, 5]. Unlike antibiotics, they do not affect normal
microbiota, are safe and eco-friendly, have no counter-indications.
Search for efficient probiont-bacteria is a priority task of modern biotechnology.
Probiotics may be derived either from normal microflora or from saprophytes atypical for gut
microbiota capable to replace pathogenic microorganisms from the intestine. Sporulating
bacteria of genus Bacillus hold a special place among probionts [6]. Probiotic bacillus strains
are non-adhesive transitory gut representatives. Valuable properties of these microorganisms
make them a vital stock for upgrading biopreparations. Primarily it's enhanced enzyme
activity allowing to regulate and stimulate digestion processes capable to the ability to exert
antiallergic, antibiotic action and to raise non-specific resistance of microorganism [7, 8].
High antagonistic activity towards a broad spectrum of strictly and facultatively pathogenic
microorganisms and auto-elimination from gastrointestinal tract makes production of
prophylactic-therapeutic agents from probiotic bacilli especially attractive.
Taking above-mentioned aspects into account, this study was focused on elaboration of
novel probiotic product based on efficient strain of sporulating Bacillus bacteria for
prevention and treatment of enteritis and respiratory diseases in cattle.
M ATERIALS AND M ETHODS
Bacterial strain Bacillus subtilis 9/9 distinguished by elevated antagonistic activity
against animal pathogens was chosen for further investigations (deposited at Collection of
non-pathogenic microbial cultures, Institute of Microbiology, National Academy of Sciences,
Belarus under registration number B 454 D) [9].
Strictly and facultatively pathogenic bacteria from collection of Institute of Experimental
Veterinary Research responsible for intestinal and pulmonary infections of farm stock -
Escherichia coli, Proteus vulgaris, Klebsiella pneumoniae, Salmonella holeraesuis,
Staphylococcus sp., Pasterella multacida, Streptococcus sp. served as test objects to evaluate
antimicrobial activity of examined culture.